title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
103 Biggest Movers From Yesterday,20220511T102237,https://www.benzinga.com/news/22/05/27130447/103-biggest-movers-from-yesterday,SGEN,0.06399,Neutral,0.011826
"Earnings Scheduled For April 28, 2022",20220428T085040,https://www.benzinga.com/news/earnings/22/04/26860440/earnings-scheduled-for-april-28-2022,SGEN,0.014477,Neutral,-0.108204
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst - Pyxis Oncology  ( NASDAQ:PYXS ) ,20230905T164314,https://www.benzinga.com/general/biotech/23/09/34244004/pyxis-oncology-m-a-spotlight-signals-potential-growth-amidst-competitive-adc-landscape-analyst,SGEN,0.277433,Neutral,0.087105
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors - Impel Pharmaceuticals  ( NASDAQ:IMPL ) ,20230412T200100,https://www.benzinga.com/pressreleases/23/04/g31776707/impel-pharmaceuticals-announces-appointment-of-darren-cline-to-the-board-of-directors,SGEN,0.054794,Neutral,0.008984
Marinus  ( MRNS )  to Sell Rare Disease PRV to Novo Nordisk,20220715T154300,https://www.zacks.com/stock/news/1953027/marinus-mrns-to-sell-rare-disease-prv-to-novo-nordisk,SGEN,0.254307,Neutral,0.083778
Vaxcyte  ( PCVX )  Completes Enrollment in Pneumococcal Disease Study,20220714T155900,https://www.zacks.com/stock/news/1952493/vaxcyte-pcvx-completes-enrollment-in-pneumococcal-disease-study,SGEN,0.246582,Neutral,0.073851
Rhythm  ( RYTM )  Surges on Upbeat Data on Lead Product Candidate,20220713T161500,https://www.zacks.com/stock/news/1951929/rhythm-rytm-surges-on-upbeat-data-on-lead-product-candidate,SGEN,0.247208,Neutral,0.096362
Pliant Therapeutics  ( PLRX )  Up on Positive Data From Lung Disease Study,20220712T150100,https://www.zacks.com/stock/news/1951160/pliant-therapeutics-plrx-up-on-positive-data-from-lung-disease-study,SGEN,0.282234,Somewhat-Bullish,0.152928
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,SGEN,0.041466,Neutral,-0.017808
"Why IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , Avenue Therapeutics  ( NASDAQ:ATXI ) ",20221014T113437,https://www.benzinga.com/news/22/10/29266749/why-imara-shares-are-trading-higher-by-over-13-here-are-22-stocks-moving-premarket,SGEN,0.072217,Neutral,0.064821
"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire",20230918T091500,https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html,SGEN,0.043108,Neutral,0.0
"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and Company",20230724T210100,https://www.prnewswire.com/news-releases/cutaneous-melanoma-market-is-predicted-to-exhibit-remarkable-growth-predicts-delveinsight--key-companies---merck-amgen-anaveon-eisai-regeneron-bms-astrazeneca-seagen-novartis-eli-lilly-and-company-301883725.html,SGEN,0.05381,Neutral,0.031999
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,SGEN,0.020404,Neutral,-0.004464
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,20230626T210100,https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html,SGEN,0.104228,Neutral,0.00218
"Illumina, Seagen And Other Big Stocks Moving Higher On Monday - Agenus  ( NASDAQ:AGEN ) , First Majestic Silver  ( NYSE:AG ) ",20230313T145550,https://www.benzinga.com/news/23/03/31322709/illumina-seagen-and-other-big-stocks-moving-higher-on-monday,SGEN,0.162802,Neutral,0.13894
"Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know - iShares Biotechnology ETF  ( NASDAQ:IBB ) , BondBloxx ETF Trust BondBloxx BB-Rated USD High Yield Corporate Bond ETF  ( ARCA:XBB ) ",20221101T200154,https://www.benzinga.com/general/biotech/22/11/29508633/provention-bios-second-try-apelliss-eye-disorder-drug-review-3-adcom-verdicts-and-more-novembers-,SGEN,0.09402,Neutral,0.0
"Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio",20230313T143200,https://www.marketwatch.com/story/regional-banks-pace-decliners-as-biotech-deals-lift-seagen-and-provention-bio-78a5d161,SGEN,0.485711,Somewhat-Bullish,0.178968
77 Stocks Moving In Tuesday's Mid-Day Session,20220510T160029,https://www.benzinga.com/news/22/05/27114947/77-stocks-moving-in-tuesdays-mid-day-session,SGEN,0.089052,Neutral,0.005701
"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte",20230918T210100,https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html,SGEN,0.023146,Neutral,0.04357
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated - Biogen  ( NASDAQ:BIIB ) ,20230728T155617,https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33444357/reatas-acquisition-fits-biogens-strategy-despite-high-cost-analyst-says-high-level-,SGEN,0.280615,Neutral,0.0
